Cells · 6 authors, 4 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This study in a mouse model of laser-induced retinal degeneration shows that the anti-fibrotic drug pirfenidone reduces expression of extracellular matrix proteins and inflammatory markers, leading to smaller scars. However, pirfenidone did not prevent long-term fibrotic responses, suggesting that earlier intervention may be needed. The findings highlight key genes (Col4a3, ICAM1, fibulin1, itgal, selp) involved in retinal wound healing and fibrosis.
**Background:** Retinal fibrosis, the final phase of photoreceptor loss in diseases like age-related macular degeneration (AMD), involves excessive extracellular matrix (ECM) deposition driven by chronic inflammation. Pirfenidone (PFD), an anti-fibrotic drug approved for idiopathic pulmonary fibrosis, inhibits TGF-β signaling and reduces pro-inflammatory cytokines. This study investigated whether PFD can reduce scar formation in a laser-induced retinal degeneration model in mice by modulating ECM composition and inflammation.
**Methods:** Adult C57BL/6J mice received laser photocoagulation (532 nm, 300 μm spot, 60 ms, 60 mV) to induce ONL damage without Bruch's membrane rupture. PFD (10 mg/kg) was administered via drinking water from day 14 post-laser until days 21, 35, or 42. A separate group received PFD until day 35 and was harvested on day 42 (D42 PFD D35). Controls received water only. Outcomes included: lesion size by OCT; cell counts in GCL, INL, ONL by H&E; protein expression of fibronectin, αSMA, collagens 1,3,4,5, versican, and IL-1β by immunohistochemistry and Western blot; IL-1β mRNA by RT-qPCR; and a 84-gene ECM/adhesion molecule array (RT2 Profiler PCR Array) at days 7,21,35,49 (laser-only) and days 21,35,42 (PFD-treated). Statistical analysis used one-way ANOVA with Bonferroni post-hoc test.
**Key Results:** In laser-only retinas, lesion size decreased until day 14 then stabilized. IL-1β showed three waves: early (day 1), intermediate (day 21), and late (day 42). Fibronectin peaked early (days 1-14) and again at day 35. αSMA peaked at day 21. Collagens 1,3,4,5 increased from day 21 onward, with collagen 1 highest at day 49. Versican protein peaked at day 40. Gene array showed 70 of 84 genes upregulated at day 49 vs control, with significant upregulation of Col4a3, Fbln1, Itgal, Icam1, and Vcan. At day 21, 73 genes were downregulated. PFD treatment significantly reduced lesion size at day 21 and day 42 (p<0.05). Cell counts in ONL increased significantly at day 35 with PFD. PFD prevented the increase in collagens 1,3,4,5 and fibronectin, keeping levels similar to non-lasered controls. IL-1β protein and mRNA remained at control levels. αSMA was not significantly elevated. Gene array after PFD showed balanced up/downregulation; Col3a1 and Col4a1 were significantly downregulated, while Mmp8, Selp, and Tgfbi were significantly upregulated at all time points. Selectins (Sele, Sell, Selp) were upregulated, suggesting endothelial activation.
**Clinical Implications:** This study demonstrates that PFD reduces ECM deposition and inflammation in a retinal wound model, leading to smaller scars and improved ONL cell survival. However, the effect was not sustained after drug withdrawal, and long-term fibrosis still occurred, indicating that earlier intervention (before day 14) or continuous treatment may be needed. The identified key genes (Col4a3, ICAM1, fibulin1, itgal, selp) are potential therapeutic targets for retinal fibrosis. PFD, already approved for pulmonary fibrosis, may be repurposed for retinal scarring conditions such as AMD or proliferative vitreoretinopathy, but further studies are needed to optimize timing and duration of treatment.